-
Off-label postpartum use of domperidone in Canada: a multidatabase cohort study
The incidence of cardiac death and ventricular tachyarrhythmia is very low in postpartum women. Although this potential increased risk is low and could not be confirmed in this large study, it should be discussed when considering treatment options for individual patients.
Q16-10Methadone containing products used for opioid use disorder
Methadone is used for the treatment of opioid use disorder and in 2014/2015, most Canadian public drug plans transitioned from a compounded formulation to a more stable pre-mixed formulation. Subsequently, there has been reports that some patients may experience decreased effectiveness with the newer methadone formulation. This project was deemed not feasible.
Q20-20Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study
There was no clear evidence that rheumatoid arthritis on bDMARDs were less likely to discontinue or switch bDMARDs if they received concomitant csDMARD therapy.
Q14-01Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study
Direct oral anticoagulants (DOACs) and warfarin provide similar effectiveness for ischemic stroke prevention for patients with NVAF in Canada. However, DOACs carry a lower risk of major bleeding and all-cause mortality compared with warfarin.
Q16-13BValidity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study
A cardiovascular mortality algorithm applied to administrative health records had moderate validity when compared to vital statistics data. Substantial variation existed across study sites representing different geographic locations and two healthcare systems, possibly reflecting different diagnostic coding practices and healthcare utilization patterns.
Sodium-glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study
SGLT2 inhibitor use was not associated with an increased risk of incident below-knee amputation compared to DPP-4 inhibitors among patients with type 2 diabetes.